ACD Seminar Series
RNAscope® Technology

April 6, 2017

University of Birmingham


Complete this form to register


April 6, 2017 

12 - 1 pm

Institute of Cancer and Genomic Sciences 
University of Birmingham
Robert Aiken Building

Seminar Room: CRB127 


The RNAscope® technology is being routinely used for tissue-based gene expression analysis for target validation, pathobiology and biomarker development in every disease area. This technology, with its capacity to provide single-cell and single-RNA molecule sensitivity in the context of complex tissue microenvironments, is an ideal tool to complement technologies like IHC, qPCR or NGS.


Dr. Tracey Perry from the Institute of Cancer and Genomic Sciences, University of Birmingham will present "Evaluating IL-10 and CD163 expression in nasopharyngeal carcinoma using RNAscope and fluorescent IHC"


In addition, this seminar will give an overview on:

Visualizing gene expression and genetic variations in tissue environments by RNAscope® and BaseScope™

  • Detect mRNAs and lncRNAs at single molecule sensitivity by RNAscope® assay
  • Target specific splice junctions for aberrant alternative splicing in cancers by BaseScope™ assay
  • Identify point mutations or gene editing by BaseScope™ assay
  • Distinguish specific homologues, paralogues, and orthologues by RNAscope® assay or BaseScope™ assay
  • Perform single cell analysis with morphological information in FFPE or frozen tissue
  • Pinpoint expression of novel RNAs of interest 

Comprehensive evaluation of the tumor-immune environment by RNAscope® and BaseScope™

  • Characterize expression profiles of various checkpoint markers and therapeutic targets in the tumor microenvironment (TME)
  • Carry out quantitative analysis of co-expression of multiple checkpoint molecules within the same cell
  • Evaluate immune function by visualizing mRNA expression of critical molecules including IFNg and other cytokines and chemokines in the TME
  • Assess the distribution of specific T cell clones, detected by specific CDR sequences, in tumoral and stromal environments
  • Go beyond the previous restriction of short sequence limitations


Tracey Perry, PhD
Inst of Cancer and Genomic Sciences
University of Birmingham


Faraia Shah (MPhil, PhD)
Sales Account Executive
Advanced Cell Diagnostics